The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine, but limited its use to older adults and people over the age of 12 with conditions that put them at risk due to the ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine for adults 65 and older, the company ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

Panel members had questions about whether a new FDA proposal to require randomized trials for vaccines in healthy adults ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

CRISPR Therapeutics announced an agreement with Sirius Therapeutics to develop and commercialize small interfering RNA (siRNA) therapies. Under the deal, CRISPR will pay $25 million in cash and $70 ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

By The Associated Press The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use ...